Tuesday, July 22, 2014





Amgen may buy cancer drug maker Onyx for $10.5B


August 25. 2013 1:38PM
Associated Press

Story Tools
PrintPrint | E-MailEMail | SaveSave | Hear Generate QR Code QR
Send to Kindle


(AP) Biotech drugmaker Amgen is reportedly close to buying cancer drug maker Onyx Pharmaceuticals for about $10.5 billion.


The New York Times reported Saturday that Amgen Inc. would buy Onyx for $125 per share. It cited people familiar with the matter. Onyx declined to comment, while Amgen did not immediately respond to inquiries.


Amgen's drugs includes Prolia for osteoporosis, Enbrel for rheumatoid arthritis and skin disorders, and Neulasta and Neupogen for fighting infection in cancer patients.


Onyx Pharmaceuticals Inc. markets a liver and kidney cancer pill called Nexavar through a partnership with Bayer AG. Sales totaled about $861 million in 2012. In July the regulators approved Onyx's Kyprolis as a treatment for a type of blood cancer.


Onyx rejected an offer from Amgen of $120 per share in June.


Associated Press


Comments
comments powered by Disqus Commenting Guidelines
Poll
Mortgage Minute


Search for New & Used Cars

Make 
Model
 
Used New All
 

Search Times Leader Classifieds to find just the home you want!

Search Times Leader Classifieds to find just what you need!

Search Pet Classifieds
Dogs Cats Other Animals



Social Media/RSS
Times Leader on Twitter
Times Leader on Youtube
Times Leader on Google+
The Times Leader on Tumblr
The Times Leader on Pinterest
Times Leader RSS Feeds